Table 1 Patient characteristics
From: Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
|  | Patients (n = 120) |
|---|---|
Age at initial diagnosis (years) | |
  < 30 | 1 (00.0) |
 30–39 | 1 (00.0) |
 40–49 | 4 (03.3) |
 50–59 | 28 (23.3) |
 60–69 | 43 (35.8) |
 70–79 | 34 (28.3) |
  ≥ 80 | 9 (07.5) |
 Mean | 65 |
Sex | |
 Female | 61 (50.8) |
 Male | 59 (49.2) |
Race | |
 White | 96 (80.0) |
 Other | 17 (14.2) |
 Unknown | 7 (05.8) |
Vital status at last follow up | |
 Alive | 60 (50.0) |
 Dead | 60 (50.0) |
Checkpoint inhibitor | |
 atezolizumab | 2 (01.7) |
 ipilimumab + nivolumab | 2 (01.7) |
 nivolumab | 79 (65.8) |
 pembrolizumab | 37 (30.8) |